Sirnaomics ^Private

Sirnaomics is a clinical-stage biopharmaceutical company developing therapeutics for critical human diseases by using RNA interference (RNAi) technology. The RNAi technology is used to discover and develop novel therapeutics with a focus on oncology, anti-fibrotic therapeutics, and viral infection. Its proprietary Polypeptide Nano-Particle (PNP) technology is used for small interfering RNA (siRNA) drug delivery. This technology allows accessing the tumor micro-environment (TME), as well as various cell types in the liver. Sirnaomics was founded by Patrick Y. Lu and David M. Evans in 2007 and is based in Gaithersburg, Maryland.